Involvement of AMP-activated protein kinase and p38 mitogen-activated protein kinase in 8-Cl-cAMP-induced growth inhibition

✍ Scribed by Jee Hae Han; Young-Ho Ahn; Ki-Young Choi; Seung Hwan Hong

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 393 KB
• Volume: 218
• Category: Article
• ISSN: 0021-9541
• DOI: 10.1002/jcp.21573

✦ Synopsis

Abstract

8‐Cl‐cAMP (8‐chloro‐cyclic AMP), which induces differentiation, growth inhibition and apoptosis in various cancer cells, has been investigated as a putative anti‐cancer drug. Although we reported that 8‐Cl‐cAMP induces growth inhibition via p38 mitogen‐activated protein kinase (MAPK) and a metabolite of 8‐Cl‐cAMP, 8‐Cl‐adenosine mediates this process, the action mechanism of 8‐Cl‐cAMP is still uncertain. In this study, it was found that 8‐Cl‐cAMP‐induced growth inhibition is mediated by AMP‐activated protein kinase (AMPK). 8‐Cl‐cAMP was shown to activate AMPK, which was also dependent on the metabolic degradation of 8‐Cl‐cAMP. A potent agonist of AMPK, 5‐aminoimidazole‐4‐carboxamide ribonucleoside (AICAR) could also induce growth inhibition and apoptosis. To further delineate the role of AMPK in 8‐Cl‐cAMP‐induced growth inhibition and apoptosis, we used two approaches: pharmacological inhibition of the enzyme with compound C and expression of a dominant negative mutant (a kinase‐dead form of AMPKα2, KD‐AMPK). AICAR was able to activate p38 MAPK and pre‐treatment with AMPK inhibitor or expression of KD‐AMPK blocked this p38 MAPK activation. Cell growth inhibition was also attenuated. Furthermore, p38 MAPK inhibitor attenuated 8‐Cl‐cAMP‐ or AICAR‐induced growth inhibition but had no effect on AMPK activation. These results demonstrate that 8‐Cl‐cAMP induced growth inhibition through AMPK activation and p38 MAPK acts downstream of AMPK in this signaling pathway. J. Cell. Physiol. 218: 104–112, 2009. © 2008 Wiley‐Liss, Inc.